Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Goodwill (2016 - 2025)

Ani Pharmaceuticals (ANIP) has disclosed Goodwill for 13 consecutive years, with $62.5 million as the latest value for Q4 2025.

  • Quarterly Goodwill rose 4.15% to $62.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $62.5 million through Dec 2025, up 4.15% year-over-year, with the annual reading at $62.5 million for FY2025, 4.15% up from the prior year.
  • Goodwill hit $62.5 million in Q4 2025 for Ani Pharmaceuticals, roughly flat from $62.5 million in the prior quarter.
  • In the past five years, Goodwill ranged from a high of $62.5 million in Q3 2025 to a low of $3.6 million in Q1 2021.
  • Historically, Goodwill has averaged $34.4 million across 5 years, with a median of $28.2 million in 2022.
  • Biggest five-year swings in Goodwill: changed 0.0% in 2021 and later skyrocketed 688.3% in 2022.
  • Year by year, Goodwill stood at $27.9 million in 2021, then increased by 1.08% to $28.2 million in 2022, then rose by 0.07% to $28.2 million in 2023, then soared by 112.57% to $60.0 million in 2024, then rose by 4.15% to $62.5 million in 2025.
  • Business Quant data shows Goodwill for ANIP at $62.5 million in Q4 2025, $62.5 million in Q3 2025, and $60.5 million in Q2 2025.